14:35:05 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Zealand Pharma är ett bioteknikbolag. Särskilt fokus återfinns inom utvecklingen av läkemedel för behandling av diabetes och diverse tarmsjukdomar. Bolaget innehar en varierad produktportfölj med separata varumärken som säljs på global nivå. Störst verksamhet finns inom den nordiska marknaden. Zealand Pharma grundades 1997 och har sitt huvudkontor i Söborg.

Kalender

2020-11-12 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-03 Ordinarie utdelning ZEAL 0.00 DKK
2020-04-02 Årsstämma 2019
2020-03-12 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-16 Kvartalsrapport 2019-Q1
2019-04-05 Ordinarie utdelning ZEAL 0.00 DKK
2019-04-04 Årsstämma 2018
2019-03-07 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-16 Kvartalsrapport 2018-Q1
2018-04-20 Ordinarie utdelning ZEAL 0.00 DKK
2018-04-19 Årsstämma 2017
2018-03-07 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-17 Kvartalsrapport 2017-Q1
2017-04-06 Ordinarie utdelning ZEAL 0.00 DKK
2017-04-05 Årsstämma 2016
2017-03-15 Bokslutskommuniké 2016
2016-11-09 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-18 Kvartalsrapport 2016-Q1
2016-04-20 Ordinarie utdelning ZEAL 0.00 DKK
2016-04-19 Årsstämma 2015
2016-03-16 Bokslutskommuniké 2015
2015-11-05 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-05-22 Kvartalsrapport 2015-Q1
2015-04-22 Ordinarie utdelning ZEAL 0.00 DKK
2015-04-21 Årsstämma 2014
2015-03-12 Bokslutskommuniké 2014
2014-03-21 Ordinarie utdelning ZEAL 0.00 DKK
2013-04-30 Ordinarie utdelning ZEAL 0.00 DKK
2012-04-26 Ordinarie utdelning ZEAL 0.00 DKK
2012-04-25 Årsstämma 2011
2011-04-29 Ordinarie utdelning
2019-08-28 08:00:00

Company announcement – No. 27 / 2019

 

Copenhagen, August 28, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of Matthew Dallas as Vice President and Chief Financial Officer, effective October 7, 2019.

“Matthew has extensive public company experience in biotechnology organizations at both the commercial and pre-commercial stages,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “He joins us at a critical point in the company’s journey as we begin commercialization efforts. I am confident that Matthew is the right leader to help us advance into the next phase of growth.”

As the chief financial officer, Mr. Dallas will report directly to Mr. Dulac and will lead the company’s finance, legal, and investor relations departments. He will join the corporate management team to set overall business strategy.

“I am thrilled to join Zealand Pharma and contribute to the company’s exciting growth trajectory,” said Matthew Dallas. “I look forward to working with the team to champion Zealand’s strong growth potential, lean biotech mindset, and ambitious strategy.”

Most recently, Mr. Dallas served as chief financial officer at Aveo Pharmaceuticals, leading finance for the publicly traded biotechnology company and was additionally responsible for investor relations, facilities and information technology. He was previously CFO at CoLucid Pharmaceuticals, which was acquired by Eli Lilly. His earlier career included positions at Genzyme, NEN Life Science Products, and Kimberly Clark. Mr. Dallas holds a bachelor’s degree in Business Administration from the University of Tennessee.

Mr. Dallas will be assisted in the transition by Ivan M. Møller, who has served as Zealand’s interim CFO since April 2019. Mr. Møller will resume full focus on his continuing role as Senior Vice President of Technical Development & Operations.

CEO Emmanuel Dulac added, “Ivan has been an invaluable team contributor while adding interim CFO to his already expansive area of responsibility. He has maintained steady financial operations through two quarters. Thank you to Ivan for his dedication and exemplary leadership.”

 

For further information, please contact:

Emmanuel Dulac, President and Chief Executive Officer
Tel.: +45 50 60 36 36, e-mail: edu@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication
Tel.: +45 50 60 37 78, e-mail: lpm@zealandpharma.com

 

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.  

 

Attachment